<DOC>
	<DOCNO>NCT02013765</DOCNO>
	<brief_summary>This study evaluate efficacy safety intravenous Herceptin patient metastatic urothelial cancer disease progression platinum-based chemotherapy . The anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Monotherapy Patients With Metastatic Urothelial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patient &gt; =18 year age ; metastatic urothelial cancer ; disease progression 1 prior platinumbased chemotherapy ; measurable disease ; HER2 overexpression ( IHC [ 2+ ] [ 3+ ] ) . concomitant chemotherapy immunotherapy ; active uncontrolled infection ; solely CNS metastasis ; clinically significant cardiac disease , advance pulmonary disease severe dyspnoea ; coexist malignancy diagnose within last 5 year , except basal cell cancer cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>